Company: HSDTW
Filing Date: 2025-07-07
Form Type: 424B5
Source: 0001104659-25-066159
Chunk: 9

Company: Solana Co
Filing Date: 2025-07-07
Form: 424B5
Chunk 9
---
 stock may be more volatile.

<div align='center'>S-3</div>

TABLE OF CONTENTS

### THE OFFERING
Common stock offered by us

Shares of our common stock having an aggregate offering price of up to $25,000,000.

Manner of offering

Sales of our common stock, if any, under this prospectus supplement and accompanying prospectus may be made in sales deemed to be “at the market offerings” as defined in Rule 415 promulgated under the Securities Act. See “Plan of Distribution” on page S-10of this prospectus supplement for a more complete description of the manner of offering.

Shares Outstanding after this Offering

3,427,761, based on an assumed offering price of $9.10 per share, the closing price of our common stock on Nasdaq on June 30, 2025.

Use of proceeds

We expect to use the net proceeds from this offering for working capital and general corporate purposes. Please see “Use of Proceeds” on page S-9.

Risk factors

Investing in our securities involves significant risks. Please read the information contained in or incorporated by reference under the heading “Risk Factors” beginning on page S-5of this prospectus supplement, and under similar headings in other documents filed after the date hereof and incorporated by reference into this prospectus supplement and the accompanying prospectus.

Nasdaq Capital Market 
 symbol

HSDT

The number of shares of our common stock to be outstanding after this offering as shown above is based on 680,509 shares outstanding as of June 30, 2025, and excludes:

•

3,593 shares of our common stock issuable upon exercise of outstanding options at a weighted average exercise price of $3,283.72 per share;

•

27,427 shares of our common stock issuable upon exercise of outstanding warrants at a weighted average exercise price of $266.92 per share; and

•

138,927 shares of our common stock to be reserved for potential future issuance pursuant to the Helius Medical Technologies, Inc. 2021 Inducement Plan (the “2021 Plan”) and the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan (the “2022 Plan”), of which we granted stock options to purchase 124,200 shares of our common stock to directors and employees of the Company on July 2, 2025.

Unless otherwise indicated, this prospectus reflects and assumes there have been no exercise of outstanding options or